Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities

by Andriy Krendyukov
Published 2020-09-01

Innovative oncology products: time to revisit the strategy development?

by Andriy Krendyukov
Published 2019-09-01

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers

by Andriy Krendyukov, Sanjay Singhvi, Markus Zabransky
Published 2021-03-01

Development and 10-year history of a biosimilar: the example of Binocrit

by Matti Aapro, Andriy Krendyukov, Nadja Höbel, Andreas Seidl, Pere Gascón
Published 2018-04-01

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rati...

by Bernardo Leon Rapoport, Matti Aapro, Marianne Paesmans, Ronwyn van Eeden, Teresa Smit, Andriy Krendyukov, Jean Klastersky
Published 2018-09-01

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

by Christian Combe, Johannes Mann, David Goldsmith, Frank Dellanna, Philippe Zaoui, Gérard London, Kris Denhaerynck, Andriy Krendyukov, Ivo Abraham, Karen MacDonald
Published 2019-03-01